Results · Apr-Jun 2026 · filed 7 Aug 2026
Entero Healthcare Solutions Q1 FY27 results
BlockbusterBlockbuster: sales up 20% or more & profit up 30% or more on the same quarter last year, with a wider operating margin.
Sales grew 38% to ₹1,940 crore from ₹1,404 crore in Apr-Jun 2025.
Operating profit grew 94% to ₹97 crore, an operating margin of 5.0% (up 1.4 points from a year ago).
Net profit grew 72% to ₹52.1 crore from ₹30.2 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +2%, net profit +15%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 1,940 | 1,404 | +38% |
| Operating profit (EBITDA) | 97.0 | 50.1 | +94% |
| Operating margin | 5.0% | 3.6% | +1.4 pts |
| Net profit | 52.1 | 30.2 | +72% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The earnings call
Entero Healthcare Apr–Jun 2026 saw consolidated revenue grow 38.2% year-on-year to ₹1,940 crore with organic growth of 19.6% on a like-for-like basis, outpacing pharmaceutical market growth of 13.8%. EBITDA margin reached 5% in the quarter, ahead of full-year guidance, driven by scale, MedTech mix & low-margin business exits.
The last 7 quarters
Filings that week
- 10 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- 8 Aug 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 7 Aug 2026Announcement under Regulation 30 (LODR)-Investor Presentation
- 7 Aug 2026Unaudited Financial Results For The Quarter Ended June 30, 2026.
- 7 Aug 2026Board Meeting Outcome for Outcome Of Board Meeting Held On August 07, 2026
- 5 Aug 2026Revised Intimation Of The Earnings Call
- 4 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.